Conservation therapy for breast cancers other than infiltrating ductal carcinoma

Pathologic review of 861 Stage I and II breast cancers yielded 152 patients (18%) with histologic types other than invasive ductal carcinoma. All patients had been treated by breast‐conserving surgery and radiotherapy, including supplemental radiation to the tumor bed. For 67 patients with predomina...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1989-04, Vol.63 (8), p.1630-1635
Hauptverfasser: Kurtz, John M., Jacquemier, Jocelyne, Torhorst, Joachim, Spitalier, Jean‐Maurice, Amalric, Robert, Hünig, Reinhard, Walther, Eike, Harder, Felix, Almendral, Alfonso, Brandone, Henri, Ayme, Yves, Roth, Jakob
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1635
container_issue 8
container_start_page 1630
container_title Cancer
container_volume 63
creator Kurtz, John M.
Jacquemier, Jocelyne
Torhorst, Joachim
Spitalier, Jean‐Maurice
Amalric, Robert
Hünig, Reinhard
Walther, Eike
Harder, Felix
Almendral, Alfonso
Brandone, Henri
Ayme, Yves
Roth, Jakob
description Pathologic review of 861 Stage I and II breast cancers yielded 152 patients (18%) with histologic types other than invasive ductal carcinoma. All patients had been treated by breast‐conserving surgery and radiotherapy, including supplemental radiation to the tumor bed. For 67 patients with predominantly lobular carcinomas, the actuarial overall 5‐year survival was 100% and 77% for node‐negative and node‐positive patients, respectively. The actuarial probability of recurrence in the treated breast (13.5% at 5 years) appeared to be somewhat greater than that observed after treatment of invasive ductal cancers (8.8% at 5 years, P = 0.11). Of 12 mammary recurrences in patients with lobular carcinoma, four occurred at a considerable distance from the original primary and seven were multifocal, involving more than one quadrant in five patients. Of 47 patients with strictly in situ carcinomas, one patient whose axillary nodal status had not been determined subsequently developed distant metastases. Three additional patients developed mammary recurrence, two at the primary tumor site and one in another quadrant. The actuarial 5‐year mammary recurrence and overall survival rates were 4% and 98%, respectively. For 27 patients with true medullary cancers, overall survival at 5 years was 90%. One localized mammary recurrence was observed at the site of the original primary. Actuarial mammary recurrence rate was 4% at 5 years. No relapse was observed in ten patients with colloid and one patient with adenoid cystic carcinoma. The authors conclude that, in addition to its well‐established efficacy in the treatment of infiltrating ductal carcinomas, the combination of tumor excision and radiotherapy appears to provide adequate local control for other histologic types as well. However, patients with lobular cancer appear to be at somewhat greater risk of mammary failure, and recurrences in such patients tend to be multifocal and multicentric.
doi_str_mv 10.1002/1097-0142(19890415)63:8<1630::AID-CNCR2820630833>3.0.CO;2-U
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78884599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78884599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4143-5830ea7d725a75cfa9e44eed21917869d43f965ebfacf2e405aacf2bd983b37c3</originalsourceid><addsrcrecordid>eNqVkF2L1DAUhoMo6-zqTxB6IbJedMxnm4wiLHXVhcURcUDw4pCmJ1rptLNJZ2X-venOOKAXgjf5ep8cXh5CKkbnjFL-glFT5pRJfs6MNlQy9bwQC_2KFYIuFhdXb_LqQ_WJa07TgxbitZjTebV8yfPVPTI7_r5PZpRSnSspvjwkpzH-SNeSK3FCTtKqOTMz8rEa-ojh1o7t0Gfjdwx2s8v8ELI6oI1j5mzvMMRsmLIE2D5re992Y0hf-m9Zs3Wj7RIWXNsPa_uIPPC2i_j4sJ-R1dvLz9X7_Hr57qq6uM6dZFLkSguKtmxSH1sq561BKRGbVIqVujCNFN4UCmtvnecoqbLToW6MFrUonTgjz_ZzN2G42WIcYd1Gh11nexy2EUqttVTGJPDrHnRhiDGgh01o1zbsgFGYfMNkDCZj8Ns3FAI0TL4Bkm_40zcIoFAtgcMqTX9yqLGt19gcZx8Ep_zpIbfR2c6HpLONR6wwSsk7zO-xn22Hu_9r-M-CfyXiF8vNq7I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78884599</pqid></control><display><type>article</type><title>Conservation therapy for breast cancers other than infiltrating ductal carcinoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kurtz, John M. ; Jacquemier, Jocelyne ; Torhorst, Joachim ; Spitalier, Jean‐Maurice ; Amalric, Robert ; Hünig, Reinhard ; Walther, Eike ; Harder, Felix ; Almendral, Alfonso ; Brandone, Henri ; Ayme, Yves ; Roth, Jakob</creator><creatorcontrib>Kurtz, John M. ; Jacquemier, Jocelyne ; Torhorst, Joachim ; Spitalier, Jean‐Maurice ; Amalric, Robert ; Hünig, Reinhard ; Walther, Eike ; Harder, Felix ; Almendral, Alfonso ; Brandone, Henri ; Ayme, Yves ; Roth, Jakob</creatorcontrib><description>Pathologic review of 861 Stage I and II breast cancers yielded 152 patients (18%) with histologic types other than invasive ductal carcinoma. All patients had been treated by breast‐conserving surgery and radiotherapy, including supplemental radiation to the tumor bed. For 67 patients with predominantly lobular carcinomas, the actuarial overall 5‐year survival was 100% and 77% for node‐negative and node‐positive patients, respectively. The actuarial probability of recurrence in the treated breast (13.5% at 5 years) appeared to be somewhat greater than that observed after treatment of invasive ductal cancers (8.8% at 5 years, P = 0.11). Of 12 mammary recurrences in patients with lobular carcinoma, four occurred at a considerable distance from the original primary and seven were multifocal, involving more than one quadrant in five patients. Of 47 patients with strictly in situ carcinomas, one patient whose axillary nodal status had not been determined subsequently developed distant metastases. Three additional patients developed mammary recurrence, two at the primary tumor site and one in another quadrant. The actuarial 5‐year mammary recurrence and overall survival rates were 4% and 98%, respectively. For 27 patients with true medullary cancers, overall survival at 5 years was 90%. One localized mammary recurrence was observed at the site of the original primary. Actuarial mammary recurrence rate was 4% at 5 years. No relapse was observed in ten patients with colloid and one patient with adenoid cystic carcinoma. The authors conclude that, in addition to its well‐established efficacy in the treatment of infiltrating ductal carcinomas, the combination of tumor excision and radiotherapy appears to provide adequate local control for other histologic types as well. However, patients with lobular cancer appear to be at somewhat greater risk of mammary failure, and recurrences in such patients tend to be multifocal and multicentric.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19890415)63:8&lt;1630::AID-CNCR2820630833&gt;3.0.CO;2-U</identifier><identifier>PMID: 2538219</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma, Mucinous - therapy ; Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Carcinoma - mortality ; Carcinoma - pathology ; Carcinoma - therapy ; Carcinoma in Situ - therapy ; Carcinoma, Intraductal, Noninfiltrating - therapy ; Chemotherapy ; Combined Modality Therapy ; Female ; Humans ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Pharmacology. Drug treatments</subject><ispartof>Cancer, 1989-04, Vol.63 (8), p.1630-1635</ispartof><rights>Copyright © 1989 American Cancer Society</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4143-5830ea7d725a75cfa9e44eed21917869d43f965ebfacf2e405aacf2bd983b37c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=6955419$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2538219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kurtz, John M.</creatorcontrib><creatorcontrib>Jacquemier, Jocelyne</creatorcontrib><creatorcontrib>Torhorst, Joachim</creatorcontrib><creatorcontrib>Spitalier, Jean‐Maurice</creatorcontrib><creatorcontrib>Amalric, Robert</creatorcontrib><creatorcontrib>Hünig, Reinhard</creatorcontrib><creatorcontrib>Walther, Eike</creatorcontrib><creatorcontrib>Harder, Felix</creatorcontrib><creatorcontrib>Almendral, Alfonso</creatorcontrib><creatorcontrib>Brandone, Henri</creatorcontrib><creatorcontrib>Ayme, Yves</creatorcontrib><creatorcontrib>Roth, Jakob</creatorcontrib><title>Conservation therapy for breast cancers other than infiltrating ductal carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Pathologic review of 861 Stage I and II breast cancers yielded 152 patients (18%) with histologic types other than invasive ductal carcinoma. All patients had been treated by breast‐conserving surgery and radiotherapy, including supplemental radiation to the tumor bed. For 67 patients with predominantly lobular carcinomas, the actuarial overall 5‐year survival was 100% and 77% for node‐negative and node‐positive patients, respectively. The actuarial probability of recurrence in the treated breast (13.5% at 5 years) appeared to be somewhat greater than that observed after treatment of invasive ductal cancers (8.8% at 5 years, P = 0.11). Of 12 mammary recurrences in patients with lobular carcinoma, four occurred at a considerable distance from the original primary and seven were multifocal, involving more than one quadrant in five patients. Of 47 patients with strictly in situ carcinomas, one patient whose axillary nodal status had not been determined subsequently developed distant metastases. Three additional patients developed mammary recurrence, two at the primary tumor site and one in another quadrant. The actuarial 5‐year mammary recurrence and overall survival rates were 4% and 98%, respectively. For 27 patients with true medullary cancers, overall survival at 5 years was 90%. One localized mammary recurrence was observed at the site of the original primary. Actuarial mammary recurrence rate was 4% at 5 years. No relapse was observed in ten patients with colloid and one patient with adenoid cystic carcinoma. The authors conclude that, in addition to its well‐established efficacy in the treatment of infiltrating ductal carcinomas, the combination of tumor excision and radiotherapy appears to provide adequate local control for other histologic types as well. However, patients with lobular cancer appear to be at somewhat greater risk of mammary failure, and recurrences in such patients tend to be multifocal and multicentric.</description><subject>Adenocarcinoma, Mucinous - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - therapy</subject><subject>Carcinoma in Situ - therapy</subject><subject>Carcinoma, Intraductal, Noninfiltrating - therapy</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF2L1DAUhoMo6-zqTxB6IbJedMxnm4wiLHXVhcURcUDw4pCmJ1rptLNJZ2X-venOOKAXgjf5ep8cXh5CKkbnjFL-glFT5pRJfs6MNlQy9bwQC_2KFYIuFhdXb_LqQ_WJa07TgxbitZjTebV8yfPVPTI7_r5PZpRSnSspvjwkpzH-SNeSK3FCTtKqOTMz8rEa-ojh1o7t0Gfjdwx2s8v8ELI6oI1j5mzvMMRsmLIE2D5re992Y0hf-m9Zs3Wj7RIWXNsPa_uIPPC2i_j4sJ-R1dvLz9X7_Hr57qq6uM6dZFLkSguKtmxSH1sq561BKRGbVIqVujCNFN4UCmtvnecoqbLToW6MFrUonTgjz_ZzN2G42WIcYd1Gh11nexy2EUqttVTGJPDrHnRhiDGgh01o1zbsgFGYfMNkDCZj8Ns3FAI0TL4Bkm_40zcIoFAtgcMqTX9yqLGt19gcZx8Ep_zpIbfR2c6HpLONR6wwSsk7zO-xn22Hu_9r-M-CfyXiF8vNq7I</recordid><startdate>19890415</startdate><enddate>19890415</enddate><creator>Kurtz, John M.</creator><creator>Jacquemier, Jocelyne</creator><creator>Torhorst, Joachim</creator><creator>Spitalier, Jean‐Maurice</creator><creator>Amalric, Robert</creator><creator>Hünig, Reinhard</creator><creator>Walther, Eike</creator><creator>Harder, Felix</creator><creator>Almendral, Alfonso</creator><creator>Brandone, Henri</creator><creator>Ayme, Yves</creator><creator>Roth, Jakob</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890415</creationdate><title>Conservation therapy for breast cancers other than infiltrating ductal carcinoma</title><author>Kurtz, John M. ; Jacquemier, Jocelyne ; Torhorst, Joachim ; Spitalier, Jean‐Maurice ; Amalric, Robert ; Hünig, Reinhard ; Walther, Eike ; Harder, Felix ; Almendral, Alfonso ; Brandone, Henri ; Ayme, Yves ; Roth, Jakob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4143-5830ea7d725a75cfa9e44eed21917869d43f965ebfacf2e405aacf2bd983b37c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adenocarcinoma, Mucinous - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - therapy</topic><topic>Carcinoma in Situ - therapy</topic><topic>Carcinoma, Intraductal, Noninfiltrating - therapy</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kurtz, John M.</creatorcontrib><creatorcontrib>Jacquemier, Jocelyne</creatorcontrib><creatorcontrib>Torhorst, Joachim</creatorcontrib><creatorcontrib>Spitalier, Jean‐Maurice</creatorcontrib><creatorcontrib>Amalric, Robert</creatorcontrib><creatorcontrib>Hünig, Reinhard</creatorcontrib><creatorcontrib>Walther, Eike</creatorcontrib><creatorcontrib>Harder, Felix</creatorcontrib><creatorcontrib>Almendral, Alfonso</creatorcontrib><creatorcontrib>Brandone, Henri</creatorcontrib><creatorcontrib>Ayme, Yves</creatorcontrib><creatorcontrib>Roth, Jakob</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kurtz, John M.</au><au>Jacquemier, Jocelyne</au><au>Torhorst, Joachim</au><au>Spitalier, Jean‐Maurice</au><au>Amalric, Robert</au><au>Hünig, Reinhard</au><au>Walther, Eike</au><au>Harder, Felix</au><au>Almendral, Alfonso</au><au>Brandone, Henri</au><au>Ayme, Yves</au><au>Roth, Jakob</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conservation therapy for breast cancers other than infiltrating ductal carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1989-04-15</date><risdate>1989</risdate><volume>63</volume><issue>8</issue><spage>1630</spage><epage>1635</epage><pages>1630-1635</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Pathologic review of 861 Stage I and II breast cancers yielded 152 patients (18%) with histologic types other than invasive ductal carcinoma. All patients had been treated by breast‐conserving surgery and radiotherapy, including supplemental radiation to the tumor bed. For 67 patients with predominantly lobular carcinomas, the actuarial overall 5‐year survival was 100% and 77% for node‐negative and node‐positive patients, respectively. The actuarial probability of recurrence in the treated breast (13.5% at 5 years) appeared to be somewhat greater than that observed after treatment of invasive ductal cancers (8.8% at 5 years, P = 0.11). Of 12 mammary recurrences in patients with lobular carcinoma, four occurred at a considerable distance from the original primary and seven were multifocal, involving more than one quadrant in five patients. Of 47 patients with strictly in situ carcinomas, one patient whose axillary nodal status had not been determined subsequently developed distant metastases. Three additional patients developed mammary recurrence, two at the primary tumor site and one in another quadrant. The actuarial 5‐year mammary recurrence and overall survival rates were 4% and 98%, respectively. For 27 patients with true medullary cancers, overall survival at 5 years was 90%. One localized mammary recurrence was observed at the site of the original primary. Actuarial mammary recurrence rate was 4% at 5 years. No relapse was observed in ten patients with colloid and one patient with adenoid cystic carcinoma. The authors conclude that, in addition to its well‐established efficacy in the treatment of infiltrating ductal carcinomas, the combination of tumor excision and radiotherapy appears to provide adequate local control for other histologic types as well. However, patients with lobular cancer appear to be at somewhat greater risk of mammary failure, and recurrences in such patients tend to be multifocal and multicentric.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>2538219</pmid><doi>10.1002/1097-0142(19890415)63:8&lt;1630::AID-CNCR2820630833&gt;3.0.CO;2-U</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1989-04, Vol.63 (8), p.1630-1635
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_78884599
source MEDLINE; Alma/SFX Local Collection
subjects Adenocarcinoma, Mucinous - therapy
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Carcinoma - mortality
Carcinoma - pathology
Carcinoma - therapy
Carcinoma in Situ - therapy
Carcinoma, Intraductal, Noninfiltrating - therapy
Chemotherapy
Combined Modality Therapy
Female
Humans
Medical sciences
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Pharmacology. Drug treatments
title Conservation therapy for breast cancers other than infiltrating ductal carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T22%3A17%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conservation%20therapy%20for%20breast%20cancers%20other%20than%20infiltrating%20ductal%20carcinoma&rft.jtitle=Cancer&rft.au=Kurtz,%20John%20M.&rft.date=1989-04-15&rft.volume=63&rft.issue=8&rft.spage=1630&rft.epage=1635&rft.pages=1630-1635&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19890415)63:8%3C1630::AID-CNCR2820630833%3E3.0.CO;2-U&rft_dat=%3Cproquest_cross%3E78884599%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78884599&rft_id=info:pmid/2538219&rfr_iscdi=true